Cell & Gene
Manufacturing CGTs: Should I Use A CDMO?
September 30, 2022
Sidley lawyers Deeona Gaskin and Raj Pai recently published an article in Cell & Gene entitled “Manufacturing CGTs: Should I Use A CDMO?” The article explains various manufacturing challenges faced by sponsors of cell and gene therapies, and considerations for companies looking to outsource manufacturing of their cell and gene therapy products to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs).
Contacts
Related Blogs
Capabilities
Suggested News & Insights
When AI Changes The Deal: Seven AI-related Considerations for Life Sciences M&A DealmakersSeptember 8, 2026Is my product a medical device? EU Court judgment clarifies that the test includes objective function and intended purpose, and provides guidance relevant to software and AI-enabled toolsAugust 31, 2026UK Looks To Modernize Medicines And Medical Device Regulation In The Era Of AIAugust 26, 2026CMS’ CY 2027 OPPS and PFS Proposed Rules Include Major Changes to Reimbursement for 340B Hospitals, Data Reporting, and Digital HealthAugust 24, 2026Through the Looking Glass: What WHA79 Reveals About the Future of Global Life SciencesAugust 2026盛德助力华健未来成功完成香港18A章项下上市项目June 23, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory